

EUROPEAN
CURRICULUM
VITAE
FORMAT



PERSONAL
INFORMATION



CLAIRE GALLOIS

PhD Student, Centre de Recherche des Cordeliers, Paris, UMR S 1138

+33 156 09 35 53

+33 670 07 43 44

claire.gallois@aphp.fr

claire.gallois2412@gmail.com

Date of birth: 24.12.1988

Place of birth: Paris, France

WORK EXPERIENCE

Department of Digestive Oncology – Hôpital Européen Georges Pompidou, Paris; France

- **Assistant of the Paris Hospitals and Senior Registrar of the Universities**
Sorbonne Paris cite, Paris Descartes University, Assistance Publique-Hôpitaux de Paris
November 2017 – November 2020

President of the Association des Gastro-entérologues Oncologues (AGEO)

- November 2017 – present

Medical residency

- November 2012 – November 2017
 - 8th semester: Radiotherapy department, Hôpital Henri Mondor, Créteil; France
 - 7th semester: Gastroenterology department, Hôpital Saint Antoine, Paris; France
 - 6th semester: Hepatology department, Hôpital Beaujon, Clichy; France
 - 5th semester: Digestive oncology department, Hôpital Européen Georges Pompidou, Paris; France
 - 4th semester: Digestive oncology department, Gustave Roussy, Villejuif; France
 - 3rd semester: Medical intensive care department, Hôpital Européen Georges Pompidou, Paris; France
 - 2nd semester: Hepato-Gastroenterology department, hospital LARiboisière, Paris; France
 - 1st semester: Hepato-Gastroenterology department, CHI Le Raincy-Montfermeil, Montfermeil; France

Master 2: Epithelia: Interface Structures, Paris Descartes University

Laboratory UMR-S1147 : personalized medicine, pharmacogenomics, therapeutic optimization.

Works led by Professor Pierre Laurent-Puig

- November 2015 – November 2016

**EDUCATION AND
TRAINING
LICENSES AND
CERTIFICATIONS**

Diploma of complementary specialized studies of oncology

- October 2018

State Diploma Doctor of Medicine

Paris Descartes University

- October 2017

Diploma of Specialized Studies of Gastroenterology and Hepatology

- September 2017

Master 2: Epithelia: Interface Structures, Paris Descartes University

- November 2016

Inter-university Diploma of Proctology

- 2014

Medical residency

- November 2012 – November 2017

National competition of medicine

Passed 15th

- 2012

Medical School: Paris 6 Pierre et Marie Curie University, Paris; France

- October 2007– October 2012

First year medical competition

Paris 6 Pierre et Marie Curie University

Passed 8th

- 2007

Science baccalaureate grades

with highest honor

- 2006

**HONOR AND
AWARDS**

- GHIF 1st prize

Nutritional risk and tolerance of chemotherapy in patients with metastatic colorectal cancer.

June 2018

- Juniors GRdig 1st prize

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

October 2016

**PROFESSIONAL
MEMBERSHIPS**

- European society of digestive oncology (ESDO) Young group
- European Society of Medical Oncology (ESMO)
- American society of Clinical Oncology (ASCO)
- Association des Gastro-entérologues Oncologues (AGEO)
- Fédération Française de Cancérologie Digestive (FFCD)

PEER REVIEWER

Performed 8 reviews for Clinics and Research in Hepatology and Gastroenterology and 1 review for Oncotarget

JOURNAL ARTICLES

Source:

Pubmed – last update:
03.06.2021Original Articles

- Lorenzo D, **Gallois C**, Lahmek P, Lesgourgues B, Champion C, Charpignon C, Faroux R, Bour B, Remy A-J, Naouri C, Picon M, Poncin E, Macaigne G, Seyrig J-A, Bernardini D, Bellaïche G, Grasset D, Henrion J, Heluwaert F, Piperaud R, Bordes G, Bourhis F, Arpurt J-P, Pariente A, Nahon S. Middle-term mortality and re-bleeding after initial diverticular bleeding: A nationwide study of 365 mostly elderly French patients. *United European Gastroenterol J.* févr 2017;5(1):119-27. **IF 3.549**
- **Gallois C**, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz J-F, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem J-L, Emile J-F, Laurent-Puig P. Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy. *Clin Cancer Res.* 19 juin 2018. **IF 10.107**
- **Gallois C**, Artru P, Lièvre A, Auclin E, Lecomte T, Locher C, Marthey L, Zaimi Y, Faroux R, Pernot S, Barret M, Taieb J. Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. *Eur J Cancer.* sept 2019;119:35-43. **IF 7.275**
- Nassar A, Phelip JM, Goéré D, Loriau J, **Gallois C**, Michel P, Penna C, Taieb J, Brouquet A, Benoist S. What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. *World J Surg.* 18 nov 2020. **IF 2.642**
- **Gallois C**, Bourillon C, Auclin E, Artru P, Lievre A, Lecomte T, Locher C, Marthey L, Faroux R, Pernot S, Barret M, Taieb J. Skeletal muscle loss under chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. *Clin Res Hepatol Gastroenterol.* jan 2021 **IF 2.807**
- Karoui M, **Gallois C**, Piessen G, Legoux J-L, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguella H, Brunetti F, Prudhomme M, Regimbeau J-M, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. *Colorectal Dis.* févr 2021. **IF 2.769**
- Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, **Gallois C**, Toucheffeu Y, Maillet M, Trouilloud I, Romptaux P, Carbonnel F, Soularue E. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. *Clin Res Hepatol Gastroenterol.* mars 2021. **IF 2.718**
- Basile D, **Gallois C**, Puglisi F, Cohen R, Goere D, Aprile G, Lepage C, Laurent-Puig P, Di Maio M, Lecomte T, Pernot S, Zaanan A, Taieb J. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. *Clin Res Hepatol Gastroenterol.* mars 2021. **IF 2.718**

Other Scientific Publications: Case Report (CR), Reviews (RW), Editorials and Letters (EL)

- CR, EL Camus M, **Gallois C**, Marteau P. Ulcerative colitis and electronic cigarette: what's the matter? *Am J Gastroenterol.* avr 2014;109(4):608-9. **IF 10.383**
- CR **Gallois C**, Hauw-Berlemont C, Richaud C, Bonacorsi S, Diehl J-L, Mainardi J-L. Fatal necrotizing fasciitis due to necrotic toxin-producing *Escherichia coli* strain. *New Microbes New Infect.* nov 2015;8:109-12. **IF 1.600**
- RW **Gallois C**, Laurent-Puig P, Taieb J. Methylator phenotype in colorectal cancer: A prognostic factor or not? *Crit Rev Oncol Hematol.* mars 2016;99:74-80. **IF 5.833**

CONFERENCE PROCEEDINGS

- CR Lorenzo D, Boissier F, Prost A, **Gallois C**, Faisy C. Bilateral temporomandibular joint dislocation after upper gastrointestinal endoscopy in an intensive care unit patient: a rare complication. *Endoscopy*. 2014;46 Suppl 1 UCTN:E538. **IF 7.341**
- RW **Gallois C**, Pernot S, Zaanen A, Taieb J. Colorectal Cancer: Why Does Side Matter? *Drugs*. 22 mai 2018. **IF 4.690**
- RW Auclin E, Zaanen A, Vernerey D, Douard R, **Gallois C**, Laurent-Puig P, Bonnetain F, Taieb J. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. *Ann Oncol*. 1 mai 2017;28(5):958-68. **IF 18.274**
- RW Palle J, Rochand A, Pernot S, **Gallois C**, Taieb J, Zaanen A. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. *Drugs*. mars 2020;80(4):401-15. **IF 4.690**
- CR Pérez-Cuadrado-Robles E, Perrod G, Benosman H, Ragot E, **Gallois C**, Cellier C, Rahmi G. Endoscopic ultrasound-guided gastrojejunostomy as a rescue therapy for gastric outlet obstruction in a patient with multiple previous procedures. *Endoscopy*. 5 août 2020. **IF 7.341**
- RW Taieb J, **Gallois C**. Adjuvant Chemotherapy for Stage III Colon Cancer. *Cancers (Basel)*. 19 sept 2020;12(9). **IF 6.126**
- CR, EL Boeken T, **Gallois C**, Douard R, Méatchi T, Martelli N, Sapoval M, Taieb J, Pellerin O. Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor. *Clin Res Hepatol Gastroenterol*. 1 nov 2020. **IF 2.807**
- CR, EL Stammer R, **Gallois C**, Taieb J, Duong J-P, Karras A, Thervet E, Lazareth H. Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer. *Eur J Cancer*. avr 2021. **IF 7.275**

Oral communications

- Gallois C, Lorenzo D, Cuillerier E, Faroux R, Bour B, Remy A-J, Morin T, Naouri C, Pariente E-A, Bernardini D, Bellaiche G, Henrion J, Lesgourgues B, Nahon S. Facteurs prédictifs de récurrence hémorragique et de mortalité au long cours des hémorragies sur angiodysplasies coliques. **ANGH congress 2013, Montélimar**.
- Gallois C, Lorenzo D, Cuillerier E, Faroux R, Bour B, Remy A-J, Morin T, Naouri C, Pariente E-A, Bernardini D, Bellaiche G, Henrion J, Lesgourgues B, Nahon S. Facteurs prédictifs de récurrence hémorragique et de mortalité au long cours des hémorragies sur angiodysplasies coliques. **JFHOD, Paris, march 2014**.
- Gallois C, Lorenzo D, Cuillerier E, Faroux R, Bour B, Remy A-J, Morin T, Naouri C, Pariente E-A, Bernardini D, Bellaiche G, Henrion J, Lesgourgues B, Nahon S. Predictive factors of recurrence and mortality in colonic angiodysplasia bleeding. **UEGW, Vienne, October 2015**.
- Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz J-F, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem J-L, Emile J-F, Laurent-Puig P. La valeur pronostique du phénotype méthylateur dans le cancer du colon. **GRdig congress, Paris, December 2016**, 1st price Junior GRdig
- Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz J-F, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem J-L, Emile J-F, Laurent-Puig P. La valeur pronostique du phénotype méthylateur dans le cancer du colon. **JFHOD congress (plenary session), Paris, March 2017**
- Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz J-F, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem J-L, Emile J-F, Laurent-Puig P. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. **ESMO congress, Madrid, October 2017**
- Gallois C, Artru P, Lièvre A, Auclin E, Lecomte T, Locher C, Marthey L, Zaimi Y, Faroux R, Pernot S, Barret M, Taieb J. Risque nutritionnel et tolérance de la chimiothérapie chez les patients atteints de

cancer colorectal métastatique. **JFHOD congress, Paris, March 2018**

- Gallois C, Artru P, Lièvre A, Auclin E, Lecomte T, Locher C, Marthey L, Zaimi Y, Faroux R, Pernot S, Barret M, Taieb J. Risque nutritionnel et tolérance de la chimiothérapie chez les patients atteints de cancer colorectal métastatique. **GHIF congress, Paris, June 2018**, 1st price mémoire DES.

Posters

- Herrera Gomez R-G, Gallois C, Adler M, Malka D, Planchard D, Pistilli B, Ducreux M, Mir O. Safety of bevacizumab in cancer patients with inflammatory bowel disease. **ASCO**, Chicago, June 2019
- Karoui M, Gallois C, Piessen G, Legoux J-L, Barbier E, De Chaisemartin C, Lecaille C, Bouché O, Ammarguella H, Brunetti F, Prudhomme M, Regimbeau J-M, Glehen O, Lièvre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J. Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers? Three years' follow-up results of the Prodigé 22 phase II randomized multicenter trial. **ASCO**, June 2020
- Gallois C, Bourillon C, Auclin E, Artru P, Lievre A, Lecomte T, Locher C, Marthey L, Faroux R, Pernot S, Barret M, Taieb J. Skeletal muscle loss under chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. **ASCO**, June 2020
- Basile D, Polano M, Buriolla S, Gallois C, Cortiula F, Corvaja C, de Scordilli M, Michelotti A, Parnofiello A, Gerratana L, Ongaro E, Andreuzzi E, Toffoli G, Buonadonna A, Mongiat M, Zaanani A, Aprile G, Canzonieri V, Taieb J, Puglisi F. Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study. **ASCO**, June 2020.
- Basile D, Polano M, Buriolla S, Gallois C, Cortiula F, Corvaja C, De Scordilli M, Michelotti A, Pelizzari G, Ongaro E, Casagrande M, Foltran L, Toffoli G, Pella N, Buonadonna A, Zaanani A, Fasola G, Aprile G, Taieb J, Puglisi F. A novel prognostic tool based on lymphocyte ratios in patients with stage III colon cancer. **ESMO**, October 2020.
- Basile D, Gallois C, Puglisi F, André T, Benoist S, Aprile G, Lepage C, Laurent-Puig P, Di Maio M, Lecomte T, Pernot S, Zaanani A, Taieb J. Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. **ESMO**, October 2020.
- Gallois C, Hafliger E, Auclin E, Perret A, Artru P, Coutzac C, Turpin A, Pellat A, Randrian V, Basile D, Faroux R, Locher C, Hautefeuille V, Dubreuil O, Palmieri LJ, Dior M, Taieb J. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study. **ESMO**, October 2020
- Tougeron D, Emile JF, Kim S, Monterydard C, Gilabert M, Bez J, Lievre A, Dahan L, Laurent-puig P, Mineur L, Coriat R, Legoux JL, Hautefeuille V, Phelip JM, Lecomte T, Sokol H, Capron C, Gallois C, Randrian V, Lepage C, Taieb J. Pembrolizumab in combination with Xelox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate : the phase II FFCD 1703-POCHI trial. **SITC**, November 2020
- Gallois C, Hafliger E, Auclin E, Perret A, Artru P, Coutzac C, Turpin A, Pellat A, Randrian V, Basile D, Faroux R, Locher C, Hautefeuille V, Dubreuil O, Palmieri LJ, Dior M, Taieb J. Chimiothérapie de première ligne à base de raltitrexed dans le cancer colorectal: une étude rétrospective de l'AGEO. **JFHOD** 2021.
- Basile D, Gallois C, Puglisi F, André T, Benoist S, Aprile G, Lepage C, Laurent-Puig P, Di Maio M, Lecomte T, Pernot S, Zaanani A, Taieb J. Attentes et pratiques sur l'utilisation de l'AND tumoral circulant dans le cancer colorectal: résultats d'un enquête franco-italienne AGEO/AIOM/GERCOR/FFCD/FRENCH. **JFHOD** 2021

TEACHING EXPERIENCE

SIAPS score : 59

- Since 2017
 - Lecturer at the Diplôme Universitaire de Cancérologie digestive, Paris V University.

- **2019-2020**
 - Teacher: role-playing exercises about doctor-patient relationship, Paris V University
- **2017-2020**
 - Clinical teaching to medical students (2nd year, and 4 to 6th year medical students, residents)
 - Lecturer for 4th year medical students, Paris V University